Mirogabalin Fails to Reduce Fibromyalgia Pain, But Shows Promise for Post-Herpetic Neuralgia in Clinical Trials

Mirogabalin Fails to Reduce Fibromyalgia Pain, But Shows Promise for Post-Herpetic Neuralgia in Clinical Trials
Japanese pharmaceutical Daiichi Sankyo recently released top-line results of its Phase 3 trials investigating the safety and efficacy of mirogabalin in the treatment of pain for patients with fibromyalgia. Results of the trials, which were called ALDAY, showed that mirogabalin did not significantly decrease daily pain scores of participating patients. Mirogabalin is an investigational drug that selectively blocks a subunit of calcium channels found in the nervous system and that participate in pain transmission and processing. The three ALDAY trials (NCT02187159NCT02187471NCT02146430) were multicenter, randomized, double-blind, placebo-controlled, 13-week studies that investigated the safety and efficacy of mirogabalin (15 mg once a day or 15 mg twice a day) as a treatment for pain in more than 3,600 patients ages 18 or older with fibromyalgia. The studies’ primary endpoint was a change in patients’ weekly average of worst daily pain scores. This average was calculated based on the daily pain scores reported by patients that best described their worst pain in the previous 24 hours.
Subscribe or to access all post and page content.